{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:45:18Z","timestamp":1785797118934,"version":"3.56.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"32","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20 GM121327"],"award-info":[{"award-number":["P20 GM121327"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["RSG-26-1507013-01-TBE-SU"],"award-info":[{"award-number":["RSG-26-1507013-01-TBE-SU"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,8,25]]},"DOI":"10.1038\/s41388-026-03893-8","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T17:58:08Z","timestamp":1783533488000},"page":"3373-3383","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SETDB1-mediated repression of RhoB promotes EMT and metastatic progression in prostate cancer"],"prefix":"10.1038","volume":"45","author":[{"given":"Han","family":"Cong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Seilani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Goettl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daheng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinpeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6613-1746","authenticated-orcid":false,"given":"Xiaoqi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6995-0264","authenticated-orcid":false,"given":"Ka-wing","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"3893_CR1","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424\u201333.","journal-title":"N Engl J Med"},{"key":"3893_CR2","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138\u201348.","journal-title":"N Engl J Med"},{"key":"3893_CR3","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1172\/JCI39104","volume":"119","author":"R Kalluri","year":"2009","unstructured":"Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119:1420\u20138.","journal-title":"J Clin Invest"},{"key":"3893_CR4","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1007\/s00018-010-0338-2","volume":"67","author":"G Ouyang","year":"2010","unstructured":"Ouyang G, Wang Z, Fang X, Liu J, Yang CJ. Molecular signaling of the epithelial to mesenchymal transition in generating and maintaining cancer stem cells. Cell Mol Life Sci. 2010;67:2605\u201318.","journal-title":"Cell Mol Life Sci"},{"key":"3893_CR5","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.1038\/onc.2010.215","volume":"29","author":"A Singh","year":"2010","unstructured":"Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29:4741\u201351.","journal-title":"Oncogene"},{"key":"3893_CR6","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","volume":"139","author":"JP Thiery","year":"2009","unstructured":"Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871\u201390.","journal-title":"Cell"},{"key":"3893_CR7","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.devcel.2008.05.009","volume":"14","author":"J Yang","year":"2008","unstructured":"Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008;14:818\u201329.","journal-title":"Dev Cell"},{"key":"3893_CR8","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s10555-013-9483-z","volume":"33","author":"RL Bitting","year":"2014","unstructured":"Bitting RL, Schaeffer D, Somarelli JA, Garcia-Blanco MA, Armstrong AJ. The role of epithelial plasticity in prostate cancer dissemination and treatment resistance. Cancer Metastasis Rev. 2014;33:441\u201368.","journal-title":"Cancer Metastasis Rev"},{"key":"3893_CR9","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1158\/0008-5472.CAN-15-2078","volume":"76","author":"SK Martin","year":"2016","unstructured":"Martin SK, Pu H, Penticuff JC, Cao Z, Horbinski C, Kyprianou N. Multinucleation and mesenchymal-to-epithelial transition alleviate resistance to combined cabazitaxel and antiandrogen therapy in advanced prostate cancer. Cancer Res. 2016;76:912\u201326.","journal-title":"Cancer Res"},{"key":"3893_CR10","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1158\/0008-5472.CAN-11-3004","volume":"72","author":"Y Sun","year":"2012","unstructured":"Sun Y, Wang BE, Leong KG, Yue P, Li L, Jhunjhunwala S, et al. Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy. Cancer Res. 2012;72:527\u201336.","journal-title":"Cancer Res"},{"key":"3893_CR11","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1158\/0008-5472.CAN-20-2906","volume":"81","author":"D Strepkos","year":"2021","unstructured":"Strepkos D, Markouli M, Klonou A, Papavassiliou AG, Piperi C. Histone methyltransferase SETDB1: a common denominator of tumorigenesis with therapeutic potential. Cancer Res. 2021;81:525\u201334.","journal-title":"Cancer Res"},{"key":"3893_CR12","doi-asserted-by":"publisher","first-page":"319","DOI":"10.4103\/1008-682X.122812","volume":"16","author":"Y Sun","year":"2014","unstructured":"Sun Y, Wei M, Ren SC, Chen R, Xu WD, Wang FB, et al. Histone methyltransferase SETDB1 is required for prostate cancer cell proliferation, migration and invasion. Asian J Androl. 2014;16:319\u201324.","journal-title":"Asian J Androl"},{"key":"3893_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13072-023-00519-1","volume":"16","author":"H Luo","year":"2023","unstructured":"Luo H, Wu X, Zhu XH, Yi X, Du D, Jiang DS. The functions of SET domain bifurcated histone lysine methyltransferase 1 (SETDB1) in biological process and disease. Epigenetics Chromatin. 2023;16:47.","journal-title":"Epigenetics Chromatin"},{"key":"3893_CR14","first-page":"817.","volume":"11","author":"M Markouli","year":"2021","unstructured":"Markouli M, Strepkos D, Piperi C. Structure, activity and function of the SETDB1 protein methyltransferase. Life (Basel). 2021;11:817.","journal-title":"Life (Basel)"},{"key":"3893_CR15","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1101\/gad.973302","volume":"16","author":"DC Schultz","year":"2002","unstructured":"Schultz DC, Ayyanathan K, Negorev D, Maul GG, Rauscher FJ. 3rd. SETDB1: a novel KAP-1-associated histone H3, lysine 9-specific methyltransferase that contributes to HP1-mediated silencing of euchromatic genes by KRAB zinc-finger proteins. Genes Dev. 2002;16:919\u201332.","journal-title":"Genes Dev"},{"key":"3893_CR16","doi-asserted-by":"publisher","first-page":"67.","DOI":"10.3390\/genes9020067","volume":"9","author":"JA Ju","year":"2018","unstructured":"Ju JA, Gilkes DM. RhoB: team oncogene or team tumor suppressor? Genes (Basel). 2018;9:67.","journal-title":"Genes (Basel)"},{"key":"3893_CR17","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1080\/21541248.2016.1253528","volume":"9","author":"FM Vega","year":"2018","unstructured":"Vega FM, Ridley AJ. The RhoB small GTPase in physiology and disease. Small GTPases. 2018;9:384\u201393.","journal-title":"Small GTPases"},{"key":"3893_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcb.2023.151313","volume":"102","author":"K Zaoui","year":"2023","unstructured":"Zaoui K, Duhamel S. RhoB as a tumor suppressor: It\u2019s all about localization. Eur J Cell Biol. 2023;102:151313.","journal-title":"Eur J Cell Biol"},{"key":"3893_CR19","doi-asserted-by":"publisher","first-page":"4611","DOI":"10.1016\/j.molcel.2022.11.010","volume":"82","author":"KW Fong","year":"2022","unstructured":"Fong KW, Zhao JC, Lu X, Kim J, Piunti A, Shilatifard A, et al. PALI1 promotes tumor growth through competitive recruitment of PRC2 to G9A-target chromatin for dual epigenetic silencing. Mol Cell. 2022;82:4611\u20134626 e4617.","journal-title":"Mol Cell"},{"key":"3893_CR20","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/978-3-030-32656-2_9","volume":"1210","author":"A DiNatale","year":"2019","unstructured":"DiNatale A, Fatatis A. The bone microenvironment in prostate cancer metastasis. Adv Exp Med Biol. 2019;1210:171\u201384.","journal-title":"Adv Exp Med Biol"},{"key":"3893_CR21","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.120076","volume":"2","author":"FM Vega","year":"2012","unstructured":"Vega FM, Colomba A, Reymond N, Thomas M, Ridley AJ. RhoB regulates cell migration through altered focal adhesion dynamics. Open Biol. 2012;2:120076.","journal-title":"Open Biol"},{"key":"3893_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-015-0085-y","volume":"13","author":"FM Vega","year":"2015","unstructured":"Vega FM, Thomas M, Reymond N, Ridley AJ. The Rho GTPase RhoB regulates cadherin expression and epithelial cell-cell interaction. Cell Commun Signal. 2015;13:6.","journal-title":"Cell Commun Signal"},{"key":"3893_CR23","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1158\/1078-0432.CCR-12-1558","volume":"19","author":"LA Byers","year":"2013","unstructured":"Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res. 2013;19:279\u201390.","journal-title":"Clin Cancer Res"},{"key":"3893_CR24","doi-asserted-by":"publisher","first-page":"12315","DOI":"10.1073\/pnas.1922207117","volume":"117","author":"JJ Alumkal","year":"2020","unstructured":"Alumkal JJ, Sun D, Lu E, Beer TM, Thomas GV, Latour E, et al. Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance. Proc Natl Acad Sci USA. 2020;117:12315\u201323.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3893_CR25","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.CD-15-1263","volume":"7","author":"JL Bishop","year":"2017","unstructured":"Bishop JL, Thaper D, Vahid S, Davies A, Ketola K, Kuruma H, et al. The master neural transcription factor BRN2 is an androgen receptor-suppressed driver of neuroendocrine differentiation in prostate cancer. Cancer Discov. 2017;7:54\u201371.","journal-title":"Cancer Discov"},{"key":"3893_CR26","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/s41556-021-00743-5","volume":"23","author":"A Davies","year":"2021","unstructured":"Davies A, Nouruzi S, Ganguli D, Namekawa T, Thaper D, Linder S, et al. An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer. Nat Cell Biol. 2021;23:1023\u201334.","journal-title":"Nat Cell Biol"},{"key":"3893_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1304342","volume":"14","author":"D Collotta","year":"2023","unstructured":"Collotta D, Bertocchi I, Chiapello E, Collino M. Antisense oligonucleotides: a novel Frontier in pharmacological strategy. Front Pharm. 2023;14:1304342.","journal-title":"Front Pharm"},{"key":"3893_CR28","doi-asserted-by":"publisher","first-page":"2004.","DOI":"10.3390\/jcm9062004","volume":"9","author":"K Dhuri","year":"2020","unstructured":"Dhuri K, Bechtold C, Quijano E, Pham H, Gupta A, Vikram A. Antisense oligonucleotides: an emerging area in drug discovery and development. J Clin Med. 2020;9:2004.","journal-title":"J Clin Med"},{"key":"3893_CR29","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1158\/0008-5472.CAN-22-0264","volume":"83","author":"Z Huang","year":"2023","unstructured":"Huang Z, Li X, Tang B, Li H, Zhang J, Sun R, et al. SETDB1 modulates degradation of phosphorylated RB and anticancer efficacy of CDK4\/6 inhibitors. Cancer Res. 2023;83:875\u201389.","journal-title":"Cancer Res"},{"key":"3893_CR30","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.3892\/ijo.2016.3378","volume":"48","author":"Q Li","year":"2016","unstructured":"Li Q, Li Y, Wang Y, Cui Z, Gong L, Qu Z, et al. Quantitative proteomic study of human prostate cancer cells with different metastatic potentials. Int J Oncol. 2016;48:1437\u201346.","journal-title":"Int J Oncol"},{"key":"3893_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57005-3","volume":"16","author":"M Uguen","year":"2025","unstructured":"Uguen M, Shell DJ, Silva M, Deng Y, Li F, Szewczyk MM, et al. Potent and selective SETDB1 covalent negative allosteric modulator reduces methyltransferase activity in cells. Nat Commun. 2025;16:1905.","journal-title":"Nat Commun"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03893-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03893-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03893-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:02:05Z","timestamp":1785794525000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03893-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":31,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2026,8,25]]}},"alternative-id":["3893"],"URL":"https:\/\/doi.org\/10.1038\/s41388-026-03893-8","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"21 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KF has grants from NIH P20 GM121327, V Foundation (V2023-014), and American Cancer Society (RSG-26-1507013-01-TBE-SU). HC, FS, RG, DH, JL, CW, XL, and RW have no conflicts of interest to declare.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}